RESEARCH

Open Access

Primary hepatic Burkitt lymphoma in a child and review of literature



Zhenhui Huang¹, Yuanxing Hu¹, Shengye He¹, Jiamin Zeng², Xin Zhang¹, Cuihong Ji¹, Haiwu Lu¹, Ping Xue¹ and Xiaofeng Jiang^{1*}

Abstract

Background Primary hepatic Burkitt lymphoma (PHBL) in children is an extremely rare hepatic malignancy with a dismal prognosis, unless it is detected and treated promptly.

Case summary An 11-year-old child with abdominal pain was admitted to our hospital. No notable abnormalities were found during his physical examination or laboratory workup, but the abdominal computed tomography and magnetic resonance imaging both indicated a malignant hepatic mass measuring 9.2×7.1×7.5 cm in size. His postoperative pathology revealed an unexpected primary hepatic Burkitt lymphoma following a laparoscopic liver lobectomy. He then received rituximab and intense multi-agent chemotherapy as treatment. Despite post-chemotherapy bone marrow suppression, the patient eventually made a full recovery and had a good overall state.

Conclusion In this study, we describe a rare case of pediatric primary hepatic Burkitt lymphoma and review the literature on clinical features, diagnosis, and treatment for primary hepatic Burkitt lymphoma in children. We stress that this diagnosis should be taken into account in the absence of other single hepatic lesions or primary tumors of hematological disorders, particularly when there is a normal AFP level.

Keywords Primary hepatic non-Hodgkin lymphoma, Primary hepatic Burkitt lymphoma, Childhood, Liver tumor

Introduction

Primary hepatic lymphoma (PHL) is a rare cancer that accounts for less than 10% of all focal hepatic lesion [1]. Among lymphoma, PHLs make up 0.4% of all extranodal lymphomas and 0.016% of all non-Hodgkin lymphomas [2]. The diffuse large B cell lymphoma (DLBCL) tissue type is frequently observed in the PHLs [3, 4]. However, Burkitt lymphoma, a kind of histological type of mature B cell non-Hodgkin's lymphoma that originates from liver without extrahepatic primary lesions, is highly

*Correspondence:

jiangxiaofeng008@163.com

¹ Department of Hepatobiliary Surgery, Second Affiliated Hospital

of Guangzhou Medical University, Guangzhou, China

uncommon in children with just eight cases reported globally (Table 1) [5-12]. We describe a rare case of primary hepatic Burkitt lymphoma (PHBL) in children in this report and review the prior literature to offer an overview of its epidemiology, etiology, clinical presentation, imaging features, pathological features, therapy, and prognosis.

Case presentation

An 11-year-old child who had been complaining of right upper quadrant ache for 10 days was hospitalized to our hospital. A large lesion that the local hospital discovered during a CT scan of his abdomen led them to believe that he most likely had liver cancer. He had no history of hypertension, coronary heart disease, diabetes, or infectious disease. His grandfather passed away from liver cirrhosis in the past, and his father carried the hepatitis B virus. Physical examination revealed that his belly was



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ficenses/by/A0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Xiaofeng Jiang

² Department of Pathology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Table 1 Clinical characteristics and treatment results of children with primary hepatic Burkitt lymphoma

No.	Year	Age/Sex N	ationality	Symptoms	Physical findings	Imagine Findings/ Extrahepatic Involvement	Size/maximal diameter(cm)	Concurrent disorder	Therapy	Survival (mo)	Dutcome	Ref
1	1988	14/M	China	Postprandial epigastralgia	Epigastric tenderness, hepatospleno- megaly	Right lobe mass,dilatation of the pancreatic duct/None	17.0	Acute pancreatitis	Lobectomy + CT(Regimen was NA)	NA	NA	5
2	1977	14/M	China	Epigastric pain, weight loss	Hepatomegaly	Right lobe mass/None	17.0×14.5×8.0	HbsAg (+) , acute pancreatitis	Lobectomy + VCR、 PDN、 DM、 A、 MTX、 Ara-C	>96	CR	6
3	1990	8/M	Nigeria	Abdominal pain , weight loss	Hepatomegaly	Right lobe mass/None	NA	None	Died four days after admission	Death	Death	12
4	2006	9/M	France	Abdominal pain , vomiting	Hepatomegaly	Bilateral lobes masses /None	18.0×17.0×11.0	None	CT (Regimen was NA)	NA	CR	7
5	2008	8.5/M	Greece	persistent fever	Lymphadenopathy in the neck, Hepatomegaly	Mutiple intrahepatic lesions/ Cervical and inguinal lymphnodes	NA	None	Ara-C VP-16	>15	CR	8
6	2009	2.5/M	Egypt	Jaundice, irritability, consciousness	Hepatomegaly, jaun dice, drowsy, edema, ascites	Multiple nodules/None	6.0×4.0	Hepatic encephalopathy	CTX, VCR, MTX, PDN	NA	CR	9
7	2011	3/M	Turkey	Abdominal distension	Hepatomegaly	Mutiple intrahepatic lesions /None	6.0	None	BFM-95	>8	CR	10
8	2021	5/M	Canada	Abdominal pain , fetigue	Hepatomegaly	Mutiple intrahepatic lesions /Both kidney	7.3×6.7×6.1	None	R+CT(CTX、VSR、PDN、 DXR、MTX Ara-C、VP-16)	>12	CR	11
9	2022	11/M	China	Abdominal pain	None	Right lobe mass/None	9.2 ×7.1 ×7.5	None	Lobectomy+R+CT(BFM- 95)	>16	CR	This study

M Man, F Female, NA not available, Ara-C Cytarabine, VP-16 Etoposide, CTX Cyclophosphamide, DXR Doxorubicin, MTX Methotrexate, PDN Prednisone, VCR Vincristine, R Rituximab, DM Daunomycin, A Asparaginase, CR Complete remission, CT chemotherapy, RT Radiotherapy, BFM Berlin-Frankfurt-Munster protocol, Ref References

soft, flat, and lacking any abdominal mass or rebound pain.

Laboratory workup for tumor markers, liver function, coagulation, blood routine, and liver function did not reveal any notable abnormalities. Our hospital's abdomen enhanced CT scan revealed that the lesion, which measured $9.2 \times 7.1 \times 7.5$ cm, was located in the hepatic segments V and VI. Additionally, it implied that the lesion might mostly be malignant. Moreover, hepatic MRI did not reveal any mesenteric or retroperitoneal lymphadenopathy, calcification, or necrosis (Fig. 1A–C). On the basis of this,we recommended him to receive the laparoscopic resection.

During surgery, a massive solid mass with unclear boundaries was discovered protruding through the surface of the right lower lobe of the liver. Particularly, the tumor was adhering to the lower omental tissue with spontaneous rupture and bleeding under the tumor mass (Fig. 1D). No extra-hepatic metastases were seen, and no enlarged lymph nodes were also detected. Following removal of the mass from the abdominal cavity, a $9.2 \times 7.1 \times 7.5$ cm tumor with localized bleeding and necrosis was discovered by pathological testing (Fig. 2). The specimen was then sent to pathology for diagnostic tests.

The surgery took 190 min, and 100 mL of blood was lost in total. After surgery, the patient made a full

recovery without any blood transfusions. Unexpectedly, the definitive diagnosis of hepatic Burkitt lymphoma (PHBL) was made. This is an uncommon hematologic cancer of the liver. Consequently, after he was discharged from our hospital, we advised that he continue his treatment in a children's specialty facility.

He received rituximab continuously along with chemotherapy in accordance with BFM Collaboration Group protocol. But frequent chemotherapy caused severe post-chemotherapy bone marrow suppression, which reduced the production of platelets, red blood cells, and white blood cells. He subsequently experienced recurrent fever and rash, although these symptoms were managed by symptomatic therapy such anti-infection, gamma globulin infusion, and blood transfusion. In the end, he successfully finished five rounds of chemotherapy within 4 months of the operation.

Follow-up

We conducted a systematic follow-up on the patient 16 months following the operation. He made a good recovery and showed no signs of fever or redness. His laboratory tests also return to normal. And his PET-CT scan results indicate that there are no signs of recurrence, which is considered achieving complete remission (CR).

Discussion

children have been reported in the literature that is cur-




Fig. 1 AT1w sequence, transverse plane, revealing a large space occupying lesion in the right lobe of liver. BT2w sequence, same plane, showing the hyper-intense signal of the lesion. CT1w sequence, coronal plane, following intravenous contrast administration. D Intraoperative picture. The tumor (red arrow) with spontaneous rupture and bleeding in the bottom was adhesion to the lower omental tissue (yellow arrow)




Fig. 2 Massive grayish white necrotic tissue was found in the dissected specimen

Although secondary liver involvement in non-Hodgkin lymphomas is frequently observed in their advanced stages, primary hepatic lymphoma (PHL) is a rare type of cancer. According to previous study, man in their middle years are most frequently affected [13, 14].PHL constitutes 0.016% of all non-Hodgkin lymphomas [2]. As a kind of histological type of mature B cell non-Hodgkin's lymphoma, Burkitt's lymphoma (BL) is a highly aggressive and quickly developing cancer. Particularly, primary hepatic Burkitt lymphoma (PHBL), defined as BL confined to the liver is exceptionally rare at any age. According to our knowledge, only eight cases of PHBL in rently available (Table 1).

Taking this present case into account, their median age was 8.4 years (range, 2.5–14 years). The clinical manifestations of PHBL are non-specific and include nausea, exhaustion, weight loss, and abdominal pain. The child only ever displayed clinical illness and symptoms of liver failure in one instance. Two cases in particular were complicated with acute pancreatitis and hepatectomy eased the symptoms. It was hypothesized that the extrinsic tumor compressing the ampulla of Vater was partially blocking the pancreatic outflow. Physical examination of PHBL may also exhibit no abnormalities. Nevertheless, common positive indications include hepatomegaly, with some instances also showing jaundice or lymphadenopathy. Corresponding with adult data [13, 14], all of the known pediatric PHBL cases are in boys, and none of them show signs of a pre-existing liver condition. In our research, the only documented fatality was that of a youngster whose diagnosis illness did not allow him to live long enough to begin therapy, and his diagnosis of PHBL was made post-mortem [11]. Nevertheless, chemotherapy alone or in combination with surgical resection worked successfully for the majority of kids.

Despite individuals with PHL being discovered to be related with a number of diseases, such as EBV, HBV, HCV, or HIV infections, liver cirrhosis, systemic lupus erythematosus, and immunosuppressive medication, the pathogenesis of PHL has not yet been thoroughly elucidated [13, 15]. Only one of the nine children in this study had HAV, and none of the others had any complications from the aforementioned illnesses. It is unfortunate that genetic screening was not done on the youngster in this circumstance. Accordingly, more pediatric case studies and analysis are required.

Owing to its rarity, PHBL may be difficult for doctors and pathologists to diagnose. Primary hepatic tumors and metastatic lesions are included in the initial differential diagnosis made only on the basis of a physical examination. It is important to distinguish primary hepatic tumor from hepatoblastoma, hepatocellular carcinoma, hepatic adenoma, and other related conditions. The diagnosis of hepatoblastoma and hepatocellular carcinoma in our patient was not supported by the normal AFP. Hepatic adenomas often appear during puberty and are linked to androgen use [10], which was not the case in our patient. Infantile hemangioendothelioma is unlikely because the disease typically manifests before the age of 6 months as a mass in the liver or with severe hepatomegaly and heart failure brought on by many arteriovenous connections inside the tumor. The biliary tract is where hepatic embryonal sarcoma develops, and it typically manifests before the age of 5. Since there are no associated symptoms, the typical presentation, which is jaundice secondary to biliary blockage, is improbable in this instance. In our situation, the possibility of a primary hepatic neuroendocrine tumor was strongly considered because it might manifest as metastatic disease without a primary tumor. Additionally, immunohistochemistry results that are positive for chromogranin A (CgA) and neuron-specific enolase (NSE) are required to support this verified diagnosis. With regard to metastatic lesions, we could quickly rule out liver metastasis from an intestine tumor using common tumor markers as CA 19–9 and CEA. Finally, the lack of a primary kidney lesion on imaging examinations allowed for the easy exclusion of a Wilms tumor.

Histopathology provides the foundation for the PHL diagnosis in its entirety. It is acceptable to diagnose liver tumors using ultrasound-guided core-needle biopsy, but malignant tumors run the danger of metastasizing along the needle tract. Laparotomy also offers the additional advantage of allowing for a better examination of the abdominal cavity to rule out the presence of extra hepatic masses. Although the histological type of the mass was unclear, we performed a laparoscopic exploration and planned biopsy since it was possible that the tumor was malignant. Upon entering the abdominal cavity, we found that the liver tumor was huge, accompanied by the appearance of spontaneous rupture and bleeding (Fig. 1D), which was further suggestive of malignancy. Laparoscopic liver resection was consequently carried out directly. Massive gravish white necrotic tissue was found in the liver following the removal of the tumor, as seen in Fig. 2. The tumor cells were identified through additional pathological analysis as tiny to medium-sized cells with basophilic cytoplasm, fatty vacuoles, round nuclei, and condensed chromatin, together with admixed macrophages that displayed the recognizable "starry-sky" appearance (Fig. 3). Immunohistochemical staining revealed the abundant presence of the markers CD20, C-myc, Bcl-6, and MUM1. The proliferation factor determined by Ki67 was > 90%, which supported the Burkitt lymphoma diagnosis (Fig. 4).

According to Table 1, PHBL most frequently happens in the right lobe of the liver when it manifests as an isolated mass. Typically, ultrasound findings show the existence of hypoechoic homogeneous masses that correlate well with CT imaging data. However, the presentation of PHBL on MRI varies, and it may present as a single or multiple nodules. In general, hepatic lymphoma is typically described as hypointense to normal liver on T1-weighted images and hyperintense to liver on T2-weighted images [9, 16].

There is currently no agreed-upon treatment for this rare case, and reports of sole surgical therapy, sole chemotherapy, or combined therapy exist. According to recent research and our case, complete surgical resection would be the preferred choice of treatment for patients with a single tumor restricted to one side of the liver when the histologic diagnosis is unknown. According to Table 1, surgical resection combined with postoperative adjuvant chemotherapy seems to be a good choice for patients with good liver function for which reduction of tumor load by surgery may be an adjunct to chemotherapy to some extent. For individuals with numerous nodules or




Fig. 3 Hematoxylin and eosin stain (HE) of the tumor tissue. **a** HE, $100 \times .$ **b** HE, $200 \times .$




Fig. 4 Immunohistochemical staining of the resected specimen. a Bcl-6(+), b CD20(+), c C-myc(+), d Ki67(+), e MUM1(+)

diffuse distribution of intrahepatic lesions, chemotherapy alone is preferable. Most pediatric oncology cooperative groups, as well as individual institutions, have reported excellent outcomes with intensive multiagent chemotherapy regimens that include cyclophosphamide, antimetabolites, anthracyclines, etoposide, vincristine, and corticosteroids in the treatment of Burkitt's lymphoma in children [4, 17, 18]. Additionally, it has been demonstrated that the level of serum lactic dehydrogenase (LDH) is suggestive to reflect the patient's tumor load [4]. In other words, the increase of serum LDH may be a sensitive indicator of poor prognosis in PHBL.

Conclusion

In conclusion, there is little knowledge about the causes and processes of pediatric PHBL, which is highly uncommon in kids and predominantly affects boys and kids in school. As a result, no established consensus treatment protocols exist at this time. It is also simple to make a mistaken diagnosis because PHBL's clinical signs and laboratory tests are not specific, and the final diagnosis is still determined by pathology. Therefore, this diagnosis should be taken into account in the absence of other single hepatic lesions or primary tumors of hematological disorders, especially when the AFP level is normal.

Abbreviations

Abbieviations							
CT	Computed tomography						
MRI	Magnetic resonance imaging						
PHL	Primary hepatic lymphoma						
PHBL	Primary hepatic Burkitt lymphoma						
DLBCL	Diffuse large B cell lymphoma						
EBV	Epstein-Barr virus						
HBV	Hepatitis B virus						
HCV	Hepatitis C virus						
HIV	Human immunodeficiency virus						
HAV	Hepatitis A virus						
CEA	Carcinoembryonal antigen						
AFP	Alpha-fetoprotein						
LDH	Lactate dehydrogenase						
CgA	Chromogranin A						
NSE	Neuron-specific enolase						
BFM	Berlin-Frankfurt-Münster protocol for B cell non-Hodgkin lymphoma						

Acknowledgements

We are grateful to the patient and his family for allowing us to participate in his care.

Authors' contributions

ZH and YH contributed equally to write the manuscript and share first authorship. XJ performed the research and revised the report. All authors (XJ, ZH, YH, SH, JZ, XZ, CJ, HL, PX) edited and reviewed the paper.

Funding

None.

Availability of data and materials

All data generated or analyzed during this study are included in the article. Further inquiries can be directed to the corresponding authors.

Declarations

Ethics approval and consent to participate

This study was reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University (approval code: 2022-hg-ks-27).

Consent for publication

Patient's consent not required as patients identity is not disclosed or compromised.

Competing interests

The authors declare no competing interests.

Received: 4 April 2023 Accepted: 26 May 2023 Published online: 24 July 2023

References

- Sans M, Andreu V, Bordas JM, et al. Usefulness of laparoscopy with liver biopsy in the assessment of liver involvement at diagnosis of Hodgkin's and non-Hodgkin's lymphomas. Gastrointest Endosc. 1998;47(5):391–5.
- Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol. 2005;53(3):199–207.
- Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92(8):2023–9.
- Peng Y, Qing AC, Cai J, Yue C, French SW, Qing X. Lymphoma of the liver: clinicopathological features of 19 patients. Exp Mol Pathol. 2016;100(2):276–80.
- Wan YL, Chen WJ, Huang SC, Lee TY, Tsai CC. Solitary hepatic Burkitt lymphoma presenting as acute pancreatitis. Pediatr Radiol. 1988;18(2):160.

- Huang CB, Eng HL, Chuang JH, Cheng YF, Chen WJ. Primary Burkitt's lymphoma of the liver: report of a case with long-term survival after surgical resection and combination chemotherapy. J Pediatr Hematol Oncol. 1997;19(2):135–8.
- Fikri M, Dafiri R. Primary hepatic lymphoma: report of a pediatric case. J Radiol. 2006;87(3):311–3.
- Mantadakis E, Raissaki M, Tzardi M, Katzilakis N, Chatzimichael A, Kalmanti M. Primary hepatic Burkitt lymphoma. Pediatr Hematol Oncol. 2008;25(4):331–8.
- 9. Al-Tonbary Y, Fouda A, El-Ashry R, Zalata K. Primary hepatic non-Hodgkin lymphoma presenting as acute hepatitis in a 2-year-old male. Hematol Oncol Stem Cell Ther. 2009;2(1):299–301.
- Citak EC, Sari I, Demirci M, Karakus C, Sahin Y. Primary hepatic Burkitt lymphoma in a child and review of literature. J Pediatr Hematol Oncol. 2011;33(8):e368–71.
- 11. Chamberlain G, Coltin H, Klaassen RJ, Story E, Abbott LS. Successful treatment of pediatric primary hepatic Burkitt lymphoma using rituximab: a case report. Pediatr Blood Cancer. 2021;68(12):e29259.
- Adeodu OO, Nwosu SO, Odunusi OE. Hepatic Burkitt lymphoma. Presentation with extremely rapid growth. Clin Pediatr (Phila). 1990;29(9):529–31.
- Ugurluer G, Miller RC, Li Y, et al. Primary hepatic lymphoma: a retrospective, multicenter rare cancer network study. Rare Tumors. 2016;8(3):6502.
- 14. Lei KI. Primary non-Hodgkin's lymphoma of the liver. Leuk Lymphoma. 1998;29(3–4):293–9.
- Dantas E, Santos J, Coelho M, et al. Primary hepatic lymphoma in a patient with cirrhosis: a case report. J Med Case Rep. 2020;14(1):168.
- Karadeniz C, Oguz A, Citak EC, et al. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center. Pediatr Hematol Oncol. 2007;24(6):417–30.
- Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9.
- Spreafico F, Massimino M, Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol. 2002;20(12):2783–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

